NCT02314208View on ClinicalTrials.gov

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

September 27, 2017

Study Completion Date

January 1, 2018

Conditions
Spastic Paraplegia, Hereditary
Interventions
DRUG

Xenbilox

DIETARY_SUPPLEMENT

Resveratrol

DRUG

Tahor

Trial Locations (1)

Unknown

Pitié-Salpêtrière Hospital, Paris

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02314208 - Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 | Biotech Hunter | Biotech Hunter